Skip to search formSkip to main contentSkip to account menu

24 HR tolterodine tartrate 2 MG Extended Release Oral Capsule

Known as: tolterodine tartrate 2 MG 24 HR Extended Release Oral Capsule, TOLTERODINE TARTRATE 2MG CAP,SA, TOLTERODINE TARTRATE 2 mg ORAL CAPSULE, EXTENDED RELEASE [Tolterodine Tartrate Extended Release] 
National Institutes of Health

Related topics

Related topics

27 relations

Broader (1)

ANTISPASMODICS,URINARY
Angle Closure GlaucomaDecreased Bladder Contractility [PE]Extended Release Oral CapsuleGelatin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
In vivo demonstration of muscarinic receptor selectivity of fesoterodine active metabolite, 5-hydroxymethl tolterodine (5-HMT), in rat tissue
2011
2011
UP.03.190 Adverse Effects of Tolterodine Tartrade and Solifenacin Succinate on the Central Nervous Systems in Children
2010
2010
Studies on the preparation, characterization and pharmacological evaluation of tolterodine PLGA microspheres.
2008
2008
Preparation and Evaluation of Tolterodine Tartarate Transdermal Films for the
Overactive bladder is a chronic, and distressing medical condition characterized by urinary urgency and frequency, with or… 
2007
2007
Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials
Early studies of extended-release oxybutynin in patients with overactive bladder used adjusted-dose regimens ranging from 5 to 30… 
2005
2005
신경인성 방광을 갖는 소아에서 tolterodine 투여의 유용성과 안전성
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)